2 results
Approved WMOPending
Main objective:•To compare the progression-free survival of imlunestrant (Arm A) to the standard comparator of Investigator's Choice Endocrine Therapy of either fulvestrant or exemestane (Arm B) in the ITT population•To compare the PFS of Arm…
Approved WMORecruiting
The aim of this study is to determine whether MI-E leads to a lower number of RTIs as compared to AS combined with MAC in DMD patients with a PECF< 270 l/min over a period of two years.